Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr Ducreux on the Potential Use of Liver Transplantation Plus Chemo for CRC Liver Metastases

October 23rd 2024

Michel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

October 21st 2024

The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.

The OncFive: Top Oncology News and Trends for the Week of 10/13

October 19th 2024

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma

October 18th 2024

The FDA approved zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

FDA Grants Orphan Drug Designation to Namodenoson for Pancreatic Cancer

October 9th 2024

The FDA has granted orphan drug designation to namodenoson for the treatment of patients with pancreatic cancer.

Dr Rutkowski on Avelumab Plus Axitinib in Unresectable/Metastatic GIST

October 8th 2024

Piotr Rutkowski, MD, discusses an investigation of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression.

Dr Janjigian on Final OS Results With Pembrolizumab Plus Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer

October 7th 2024

Yelena Y. Janjigian, MD, discusses final overall survival data from the phase 3 KEYNOTE-811 trial in HER2-positive metastatic gastric or GEJ adenocarcinoma.

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

October 7th 2024

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

October 7th 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

The OncFive: Top Oncology Articles for the Week 9/22

September 28th 2024

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

September 26th 2024

The FDA’s ODAC voted against the risk:benefit profile of anti–PD-1 therapy in first-line metastatic ESCC with a PD-L1 of less than 1.

Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ Cancer

September 26th 2024

Ruihua Xu, MD, PhD, discusses data from a phase 1 trial investigating the CLDN18.2-targeted antibody-drug conjugate SHR-A1904 in gastric/GEJ cancer.

Toripalimab Plus Chemo Wins European Approval for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

September 25th 2024

The European Commission has approved toripalimab in indications for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer

September 24th 2024

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.

Phase 2 Data Point to Potential Predictive Biomarkers for Benefit With Second-Line CM24 Combo in PDAC

September 21st 2024

Serum MPO, CEACAM1 positivity, and PD-L1 CPS could predict benefit with CM24-based therapy in second-line pancreatic ductal adenocarcinoma.

FDA Grants Orphan Drug Designation to CF33-hNIS for Cholangiocarcinoma

September 18th 2024

The FDA has granted orphan drug designation to the novel oncolytic virotherapy CF33-hNIS for cholangiocarcinoma.

Tislelizumab Receives Israeli Approval in Unresectable or Metastatic ESCC

September 17th 2024

Tislelizumab has been approved by the Israeli Ministry of Health for pretreated patients with unresectable or metastatic esophageal squamous cell carcinoma.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

September 16th 2024

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Retifanlimab Plus Carboplatin and Paclitaxel Offers PFS Benefit in Recurrent/Metastatic SCAC

September 14th 2024

The addition of retifanlimab to carboplatin and paclitaxel prolonged PFS for patients with chemotherapy-naive recurrent or metastatic SCAC.